Literature DB >> 7536856

Guanidino compound metabolism in rats subjected to 20% to 90% nephrectomy.

O Levillain1, B Marescau, P P de Deyn.   

Abstract

In mammalian kidney, the proximal convoluted tubule (PCT) is the main site of arginine (Arg) production. Arginine can be used in the biosynthesis of guanidino compounds (GC). Since uremic rats have a lower functional mass of PCT, GC synthesis might be modified, especially that of guanidinoacetic acid (GAA) which occurs in PCT. In order to study GC metabolism at different steps of uremia, rats were subjected to either 42% or 80% nephrectomy (NX); the experiment lasted for three weeks. Results show that: (1) in plasma, the pattern of GC levels in 42% NX rats was similar to that of controls except for a clear increase of beta-guanidinopropionic acid (beta-GPA), whereas in 80% NX rats, all GC levels sharply increased except that of creatine which decreased. (2) Urinary excretion of GC in control and 42% NX rats is quite similar except for GAA which strongly decreased, and for homoarginine (HArg) and argininic acid (ArgA) which increased. In rats with 80% NX, the principal modification in GC excretion was a four- to five-fold reduction in GAA output. (3) After induction of renal failure, Arg, creatine and guanidinosuccinic acid reabsorption remained unchanged, and that of HArg decreased. For guanidine and methylguanidine the negative renal balance remained unchanged, and that of gamma-guanidinobutyric acid, GAA and alpha-keto-delta-guanidinovaleric acid became smaller, suggesting a better reabsorption. In conclusion, uremia strongly modified GC metabolism involving mainly those synthesized from Arg; both GAA and creatine synthesis were strongly decreased probably because of the loss of renal tissue, mainly PCT.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7536856     DOI: 10.1038/ki.1995.59

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  7 in total

1.  Disturbed metabolism of guanidino compounds characterized by elevated excretion of beta-guanidinopropionic acid and gamma-guanidinobutyric acid--an effect of vigabatrin treatment?

Authors:  A Schulze; E Mayatepek; S Frank; B Marescau; P P De Deyn; P Bachert
Journal:  J Inherit Metab Dis       Date:  1998-06       Impact factor: 4.982

2.  Behavioural deficits during the acute phase of mild renal failure in mice.

Authors:  M Al Banchaabouchi; R D'Hooge; B Marescau; P P De Deyn
Journal:  Metab Brain Dis       Date:  1999-09       Impact factor: 3.584

3.  Metabolomic profiling of the autosomal dominant polycystic kidney disease rat model.

Authors:  Takafumi Toyohara; Takehiro Suzuki; Yasutoshi Akiyama; Daisuke Yoshihara; Yoichi Takeuchi; Eikan Mishima; Koichi Kikuchi; Chitose Suzuki; Masayuki Tanemoto; Sadayoshi Ito; Shizuko Nagao; Tomoyoshi Soga; Takaaki Abe
Journal:  Clin Exp Nephrol       Date:  2011-06-22       Impact factor: 2.801

4.  Renal handling of guanidino compounds in rat and rabbit.

Authors:  O Levillain; B Marescau; P P De Deyn
Journal:  J Physiol       Date:  1997-03-01       Impact factor: 5.182

5.  Homoarginine and mortality in pre-dialysis chronic kidney disease (CKD) patients.

Authors:  Pietro Ravani; Renke Maas; Fabio Malberti; Paola Pecchini; Maren Mieth; Robert Quinn; Giovanni Tripepi; Francesca Mallamaci; Carmine Zoccali
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

6.  Exploring blood alterations in chronic kidney disease and haemodialysis using metabolomics.

Authors:  Yoric Gagnebin; David A Jaques; Serge Rudaz; Sophie de Seigneux; Julien Boccard; Belén Ponte
Journal:  Sci Rep       Date:  2020-11-11       Impact factor: 4.379

7.  Kidney Mass Reduction Leads to l-Arginine Metabolism-Dependent Blood Pressure Increase in Mice.

Authors:  Samyuktha Muralidharan Pillai; Petra Seebeck; Ralph Fingerhut; Ji Huang; Xiu-Fen Ming; Zhihong Yang; François Verrey
Journal:  J Am Heart Assoc       Date:  2018-02-25       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.